The most common projected cancers in adults were lung cancer, colon cancer, leukemia, bladder cancer, and stomach cancer.

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.